New MRI technique shows promise in detecting prostate lesions

"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

“We saw in the survey that men are concerned with how the health decisions they make now will affect them in the future,” says Petar Bajic, MD.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

Olaparib plus abiraterone and prednisone or prednisolone was granted FDA approval in May 2023 for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated mCRPC.